Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP9X | Q93008 | 11/20 | 1.00 |
| ▸ | UCHL1 | P09936 | 1/20 | 1.00 |
| ▸ | USP5 | P45974 | 1/20 | 1.00 |
| ▸ | STAT3 | P40763 | 1/20 | 0.72 |
| ▸ | USP24 | Q9UPU5 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | RGS12 | O14924 | 1/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1317674 | 1.00 | USP9X (1.00) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL1317671 | 1.00 | USP9X (1.00) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL1317669 | 1.00 | USP9X (1.00) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL21592386 | 0.92 | USP9X (0.85) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL864886 | 0.92 | USP9X (0.85) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL864885 | 0.92 | USP9X (0.85) | USP9XUCHL1USP5STAT3USP24 | |
| SCHEMBL1315701 | 0.92 | USP9X (0.85) | USP9XUCHL1USP5STAT3ALDH1A1 | |
| SCHEMBL1315698 | 0.92 | USP9X (0.85) | USP9XUCHL1USP5STAT3ALDH1A1 | |
| SCHEMBL1315700 | 0.92 | USP9X (0.85) | USP9XUCHL1USP5STAT3ALDH1A1 | |
| SCHEMBL1315703 | 0.92 | USP9X (0.85) | USP9XUCHL1USP5STAT3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262167-A1 | COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2025-08-21 | — | — | US | claimed |
| CN-119909183-A | Application of USP9X inhibitor in preparing ovarian cancer treatment drug and combined drug for improving ovarian cancer chemotherapeutic drug effect | 天津康巢生物医药股份有限公司 | 2025-05-02 | — | — | CN | claimed |
| US-20250129430-A1 | HIGH ATP-AFFINITY PROTEIN AS THERAPEUTIC TARGET FOR INTRACTABLE CANCER MOLECULAR SUBTYPES AND INHIBITOR THEREOF | VeraVerse Co., Ltd. (KR) | 2025-04-24 | — | — | US | claimed |
| EP-4442840-A1 | HIGH ATP-AFFINITY PROTEIN AS THERAPEUTIC TARGET FOR INTRACTABLE CANCER MOLECULAR SUBTYPES AND INHIBITOR THEREOF | Veraverse Co., Ltd. (KR) | 2024-10-09 | — | — | EP | claimed |
| CN-118525105-A | High ATP affinity proteins and inhibitors thereof as targets for treatment of refractory molecular subtype cancers | 维拉沃斯公司 | 2024-08-20 | — | — | CN | claimed |
| CN-118203576-A | Application of combination of USP5 inhibitor and PD-1 antibody in preparation of antitumor drugs | 重庆医科大学附属第二医院 | 2024-06-18 | — | — | CN | claimed |
| US-20240118266-A1 | CELL DEATH BIOMARKER | UCL BUSINESS PLC (GB) | 2024-04-11 | — | — | US | claimed |
| CN-113786409-B | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | 甫康（上海）健康科技有限责任公司 | 2024-04-02 | — | — | CN | claimed |
| WO-2023204640-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF GASTRIC MUCOSAL DAMAGE-RELATED DISEASES CAUSED BY HELICOBACTER PYLORI AND PLATFORM FOR SCREENING FOR ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF HELICOBACTER PYLORI INFECTION | 한국생명공학연구원 | 2023-10-26 | — | — | WO | claimed |
| EP-4213901-A1 | COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION | Massachusetts Institute of Technology (US) | 2023-07-26 | — | — | EP | claimed |
| CN-116368384-A | Compounds, targets and pathways for macrophage modulation | 麻省理工学院 | 2023-06-30 | — | — | CN | claimed |
| WO-2023085716-A1 | HIGH ATP-AFFINITY PROTEIN AS THERAPEUTIC TARGET FOR INTRACTABLE CANCER MOLECULAR SUBTYPES AND INHIBITOR THEREOF | 연세대학교 산학협력단 | 2023-05-19 | — | — | WO | claimed |
| US-20230123585-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CANCER USING DEUBIQUITINASE INHIBITORS | UNIV CHICAGO (US) | 2023-04-20 | — | — | US | claimed |
| EP-3337477-B1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | CONVALIFE SHANGHAI CO LTD (CN) | 2023-02-01 | — | — | EP | claimed |
| EP-3674300-B1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD (CA) | 2022-10-12 | — | — | EP | claimed |
| US-11446306-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2022-09-20 | — | — | US | claimed |
| US-20220111019-A1 | BRCA1 MODULATING COMPOUNDS, FORMULATIONS THEREOF, AND USES THEREOF | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2022-04-14 | — | — | US | claimed |
| US-20220087950-A1 | COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-24 | — | — | US | claimed |
| WO-2022060466-A1 | COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-03-24 | — | — | WO | claimed |
| US-20260128175-A1 | Methods and Systems for Analysis of Gene Expression Data | AMPEL BIOSOLUTIONS LLC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260125760-A1 | METHODS OF TREATMENT AND DIAGNOSIS | HUDSON INST OF MEDICAL RESEARCH (AU) | 2026-05-07 | — | — | US | disclosed |
| US-20260109694-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12599592-B2 | Therapeutic small molecules for treatment of pulmonary hypertension | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260097224-A1 | METHODS FOR MODULATING NEUROPLASTICITY | AMPA INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4720059-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | KUMQUAT BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12548678-B2 | Methods and systems for machine learning analysis of single nucleotide polymorphisms in lupus | AMPEL BIOSOLUTIONS, LLC (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SCIPHER MEDICINE CORP (US) | 2026-01-22 | — | — | US | disclosed |
| US-12503464-B2 | 1,2,5-thiadiazolidin-3-one 1,1-dioxide containing compounds and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12475972-B2 | Prediction system for identifying key heterogeneous molecules driving tumor metastasis | NANJING HANWEI PUBLIC HEALTH TECHNOLOGY CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| EP-4443437-B1 | PREDICTION SYSTEM FOR IDENTIFYING KEY HETEROGENEOUS MOLECULES THAT DRIVE TUMOR METASTASIS | NANJING HANWEI PUBLIC HEALTH TECH CO LTD (CN) | 2025-11-05 | — | — | EP | disclosed |
| CN-120789060-A | Use of Degrasyn (WP 1130) as PTBP1 degrading agent in preparation of DMD therapeutic drug | 中国药科大学 | 2025-10-17 | — | — | CN | disclosed |
| CN-120789060-A | Use of Degrasyn (WP 1130) as PTBP1 degrading agent in preparation of DMD therapeutic drug | 中国药科大学 | 2025-10-17 | — | — | CN | disclosed |
| US-20250304570-A1 | BENZO-FUSED N-HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250295659-A1 | METHODS FOR TREATING TRAUMATIC BRAIN INJURY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250296927-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2025-09-25 | — | — | US | disclosed |
| CN-120678923-A | Application of USP9X as target in preparation of medicament for treating psoriasis | 中国人民解放军空军军医大学 | 2025-09-23 | — | — | CN | disclosed |
| US-12419891-B2 | Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same | DUKE UNIVERSITY (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250288572-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY VASCULAR DISEASE | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2025-09-18 | — | — | US | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250262167-A1 | COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2025-08-21 | — | — | US | disclosed |
| US-20250223580-A1 | PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS | THE BROAD INSTITUTE, INC. | 2025-07-10 | — | — | US | disclosed |
| EP-3515559-B1 | COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORS | DANA FARBER CANCER INST INC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| CN-119909183-A | Application of USP9X inhibitor in preparing ovarian cancer treatment drug and combined drug for improving ovarian cancer chemotherapeutic drug effect | 天津康巢生物医药股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20250129430-A1 | HIGH ATP-AFFINITY PROTEIN AS THERAPEUTIC TARGET FOR INTRACTABLE CANCER MOLECULAR SUBTYPES AND INHIBITOR THEREOF | VeraVerse Co., Ltd. (KR) | 2025-04-24 | — | — | US | disclosed |
| US-12281301-B2 | Sequencing-based proteomics | THE BROAD INSTITUTE, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-12257254-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2025-03-25 | — | — | US | disclosed |
| WO-2025053670-A1 | VANILLIC ACID DERIVATIVE COMPOUND, THERAPEUTIC AGENT COMPOSITION FOR ALZHEIMER'S DISEASE COMPRISING SAME, AND THERAPEUTIC AGENT COMPOSITION FOR NEUROINFLAMMATION | 주식회사 테라노큐어 | 2025-03-13 | — | — | WO | disclosed |
| US-12195490-B2 | STRAD-binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-14 | — | — | US | disclosed |
| US-12168640-B2 | USP9X inhibitors | ProDeg, LLC (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240398828-A1 | HETERO-ATOM CONTAINING COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| WO-2024243441-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20240390370-A1 | Compositions for the Treatment of Pathogenic- And/Or Chemical-Induced Lung Injury and for the Treatment of Cancer and Methods of Using Same | DUKE UNIVERSITY | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| EP-4455136-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | Scinnohub Pharmaceutical Co., Ltd. (CN) | 2024-10-30 | — | — | EP | disclosed |
| EP-4442840-A1 | HIGH ATP-AFFINITY PROTEIN AS THERAPEUTIC TARGET FOR INTRACTABLE CANCER MOLECULAR SUBTYPES AND INHIBITOR THEREOF | Veraverse Co., Ltd. (KR) | 2024-10-09 | — | — | EP | disclosed |
| EP-4443437-A1 | PREDICTION SYSTEM FOR IDENTIFYING KEY HETEROGENEOUS MOLECULES THAT DRIVE TUMOR METASTASIS | Nanjing Hanwei Public Health Technology Co., Ltd. (CN) | 2024-10-09 | — | — | EP | disclosed |
| EP-4436967-A1 | HETERO-ATOM CONTAINING COMPOUNDS AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-4433462-A1 | USP9X INHIBITORS | Prodeg, LLC (US) | 2024-09-25 | — | — | EP | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-20240294467-A1 | USP9X Inhibitors | ProDeg, LLC | 2024-09-05 | — | — | US | disclosed |
| CN-118556056-A | Heteroatom-containing compounds and uses thereof | 金橘生物科技公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20240282453-A1 | METHODS AND SYSTEMS FOR MACHINE LEARNING ANALYSIS OF SINGLE NUCLEOTIDE POLYMORPHISMS IN LUPUS | AMPEL BIOSOLUTIONS, LLC | 2024-08-22 | — | — | US | disclosed |
| CN-118525105-A | High ATP affinity proteins and inhibitors thereof as targets for treatment of refractory molecular subtype cancers | 维拉沃斯公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-118510768-A | Diazasulfinyl structure-containing compounds and their use in medicine | 赛诺哈勃药业（成都）有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-112794878-B | Deubiquitinase activity probe and preparation and application thereof | 中国科学院上海有机化学研究所 | 2024-08-16 | — | — | CN | disclosed |
| US-20240221867-A1 | PREDICTION SYSTEM FOR IDENTIFYING KEY HETEROGENEOUS MOLECULES DRIVING TUMOR METASTASIS | NANJING HANWEI PUBLIC HEALTH TECHNOLOGY CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240203555-A1 | METHODS AND SYSTEMS FOR THERAPY MONITORING AND TRIAL DESIGN | SCIPHER MEDICINE CORP (US) | 2024-06-20 | — | — | US | disclosed |
| CN-118203576-A | Application of combination of USP5 inhibitor and PD-1 antibody in preparation of antitumor drugs | 重庆医科大学附属第二医院 | 2024-06-18 | — | — | CN | disclosed |
| CN-118203576-A | Application of combination of USP5 inhibitor and PD-1 antibody in preparation of antitumor drugs | 重庆医科大学附属第二医院 | 2024-06-18 | — | — | CN | disclosed |
| US-11993775-B2 | Ubiquitin-specific peptidase 24 inhibitor, medicinal composition and method of delaying or reversing multidrug resistance in cancers using the same | NATIONAL CHENG KUNG UNIVERSITY (TW) | 2024-05-28 | — | — | US | disclosed |
| US-20240166641-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-05-23 | — | — | US | disclosed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20240153580-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | Scipher Medicine Corporation | 2024-05-09 | — | — | US | disclosed |
| US-11971402-B2 | Methods and reagents for determination and treatment of organotropic metastasis | CORNELL UNIVERSITY (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240118266-A1 | CELL DEATH BIOMARKER | UCL BUSINESS PLC (GB) | 2024-04-11 | — | — | US | disclosed |
| US-11946094-B2 | Combination therapies and methods of use thereof | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| WO-2024059041-A1 | BENZO-FUSED N-HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11925654-B2 | Esters of 2-deoxy-monosaccharides with anti proliferative activity | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-03-12 | — | — | US | disclosed |
| CN-117542442-A | Screening and anti-myeloma application of targeted c-Maf small molecule inhibitor | 徐州医科大学 | 2024-02-09 | — | — | CN | disclosed |
| US-11883401-B2 | Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same | DUKE UNIVERSITY (US) | 2024-01-30 | — | — | US | disclosed |
| EP-4305030-A1 | HETEROCYCLES AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11859014-B2 | Peptidomimetics for the treatment of Norovirus infection | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11859014-B2 | Peptidomimetics for the treatment of Norovirus infection | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11859014-B2 | Peptidomimetics for the treatment of Norovirus infection | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230414590-A1 | THERAPEUTIC SMALL MOLECULES FOR TREATMENT OF PULMONARY HYPERTENSION | THE TEXAS A&M UNIVERSITY SYSTEM | 2023-12-28 | — | — | US | disclosed |
| US-11827611-B2 | Ubiquitin-specific peptidase 24 inhibitor, medicinal composition including the same and method of delaying or reversing multidrug resistance in cancers using the same | NATIONAL CHENG KUNG UNIVERSITY (TW) | 2023-11-28 | — | — | US | disclosed |
| US-20230364061-A1 | THIAZOLIDINE DERIVATIVES FOR INHIBITING CAV3.2-USP5 INTERACTIONS | ZYMEDYNE THERAPEUTICS INC. (CA) | 2023-11-16 | — | — | US | disclosed |
| US-20230364243-A1 | CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2023204640-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF GASTRIC MUCOSAL DAMAGE-RELATED DISEASES CAUSED BY HELICOBACTER PYLORI AND PLATFORM FOR SCREENING FOR ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF HELICOBACTER PYLORI INFECTION | 한국생명공학연구원 | 2023-10-26 | — | — | WO | disclosed |
| US-11789012-B2 | Cell death biomarker | UCL BUSINESS LTD (GB) | 2023-10-17 | — | — | US | disclosed |
| US-20230310437-A1 | TTP PHOSPHORYLATION FOR THE IDENTIFICATION OF PERSONALIZED MEDICINES | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-10-05 | — | — | US | disclosed |
| EP-3434788-B1 | CLASSIFICATION AND ACTIONABILITY INDICES FOR LUNG CANCER | LIFE TECHNOLOGIES CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023150147-A1 | METHOD OF PREVENTING HEARING LOSS | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-08-10 | — | — | WO | disclosed |
| EP-4213901-A1 | COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION | Massachusetts Institute of Technology (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230227418-A1 | USP9X INHIBITORS | ProDeg, LLC | 2023-07-20 | — | — | US | disclosed |
| US-11691945-B2 | USP9X inhibitors | ProDeg, LLC (US) | 2023-07-04 | — | — | US | disclosed |
| CN-116368384-A | Compounds, targets and pathways for macrophage modulation | 麻省理工学院 | 2023-06-30 | — | — | CN | disclosed |
| WO-2023116774-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | 赛诺哈勃药业（成都）有限公司 | 2023-06-29 | — | — | WO | disclosed |
| WO-2023097927-A1 | PREDICTION SYSTEM FOR IDENTIFYING KEY HETEROGENEOUS MOLECULES THAT DRIVE TUMOR METASTASIS | 周建伟 | 2023-06-08 | — | — | WO | disclosed |
| WO-2023096928-A1 | HETERO-ATOM CONTAINING COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20230160878-A1 | METHOD OF SCREENING A THERAPY FOR INDUCTION OF FERROPTOSIS | ARPEGGIO BIOSCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023089601-A2 | USP9X INHIBITORS | ProDeg, LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| US-20230159916-A1 | METHODS OF FUNCTIONAL LINKAGE OF CHROMOSOMAL POSITIONS | ARPEGGIO BIOSCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| WO-2023091464-A1 | USP9X INHIBITORS | ProDeg, LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023085716-A1 | HIGH ATP-AFFINITY PROTEIN AS THERAPEUTIC TARGET FOR INTRACTABLE CANCER MOLECULAR SUBTYPES AND INHIBITOR THEREOF | 연세대학교 산학협력단 | 2023-05-19 | — | — | WO | disclosed |
| US-20230150925-A1 | USP9X INHIBITORS | ProDeg, LLC | 2023-05-18 | — | — | US | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
| US-20230142981-A1 | METHOD FOR IDENTIFING A MARKER FOR A BIOLOGICAL INTERACTION | ARPEGGIO BIOSCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230123585-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING CANCER USING DEUBIQUITINASE INHIBITORS | UNIV CHICAGO (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230087443-A1 | ENHANCEMENT OF CD47 BLOCKADE THERAPY BY PROTEASOME INHIBITORS | PF ARGENTUM IP HOLDINGS LLC (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230092294-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE RESPONSE | KUMQUAT BIOSCIENCES INC. | 2023-03-23 | — | — | US | disclosed |
| EP-4150623-A2 | METHODS AND SYSTEMS FOR MACHINE LEARNING ANALYSIS OF SINGLE NUCLEOTIDE POLYMORPHISMS IN LUPUS | Ampel Biosolutions, LLC (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20230066999-A1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | KARUS THERAPEUTICS LIMITED (GB) | 2023-03-02 | — | — | US | disclosed |
| US-20230044323-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | KUMQUAT BIOSCIENCES INC. | 2023-02-09 | — | — | US | disclosed |
| EP-3337477-B1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | CONVALIFE SHANGHAI CO LTD (CN) | 2023-02-01 | — | — | EP | disclosed |
| WO-2022165185-A9 | CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| CN-112206323-B | Application of USP9x inhibitor in preparation of medicine for treating osteosarcoma | 上海交通大学医学院 | 2022-11-25 | — | — | CN | disclosed |
| US-11491206-B1 | Compositions and methods for the treatment of trail-resistant cancer | DUKE UNIVERSITY (US) | 2022-11-08 | — | — | US | disclosed |
| EP-4073242-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | Kumquat Biosciences Inc. (US) | 2022-10-19 | — | — | EP | disclosed |
| EP-3674300-B1 | NOVEL BICYCLIC BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD (CA) | 2022-10-12 | — | — | EP | disclosed |
| CN-115103907-A | Compositions and methods for enhancing immune activity | 金橘生物科技公司 | 2022-09-23 | — | — | CN | disclosed |
| US-11446315-B2 | Enhancement of CD47 blockade therapy by proteasome inhibitors | PF ARGENTUM IP HOLDINGS LLC (US) | 2022-09-20 | — | — | US | disclosed |
| US-11446306-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| WO-2022192598-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| US-20220288207-A1 | PHOTO INDUCED CONTROL OF PROTEIN DESTRUCTION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| WO-2022165185-A1 | CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| CN-114652837-A | Use of USP14 inhibitor for treating sepsis | 南京医科大学 | 2022-06-24 | — | — | CN | disclosed |
| CN-114652837-A | Use of USP14 inhibitor for treating sepsis | 南京医科大学 | 2022-06-24 | — | — | CN | disclosed |
| WO-2022103706-A1 | THERAPEUTIC SMALL MOLECULES FOR TREATMENT OF PULMONARY HYPERTENSION | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-19 | — | — | WO | disclosed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| US-20220111019-A1 | BRCA1 MODULATING COMPOUNDS, FORMULATIONS THEREOF, AND USES THEREOF | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2022-04-14 | — | — | US | disclosed |
| US-11291669-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | KARUS THERAPEUTICS LIMITED (GB) | 2022-04-05 | — | — | US | disclosed |
| WO-2022061460-A1 | THIAZOLIDINE DERIVATIVES FOR INHIBITING CAV3.2-USP5 INTERACTIONS | ZYMEDYNE THERAPEUTICS INC. (CA) | 2022-03-31 | — | — | WO | disclosed |
| US-20220087950-A1 | COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-24 | — | — | US | disclosed |
| WO-2022060466-A1 | COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220041597-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2022-02-10 | — | — | US | disclosed |
| US-20210395300-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | UNIV EMORY (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210283139-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | AMPHISTA THERAPEUTICS LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| US-11021513-B2 | Peptidomimetics for the treatment of norovirus infection | EMORY UNIVERSITY (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3166604-B1 | SUBSTANCES FOR THE TREATMENT OF RETROVIRAL INFECTIOUS DISEASES | IMMUNOLOGIK GMBH (DE) | 2020-11-18 | — | — | EP | disclosed |
| US-20200325130-A1 | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | UNIV YALE (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200325130-A1 | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | UNIV YALE (US) | 2020-10-15 | — | — | US | disclosed |
| EP-3199181-B1 | ANTI-INFLUENZA VIRUS AGENT, AND SCREENING METHOD FOR ANTI-INFLUENZA VIRUS AGENT | JAPAN SCIENCE & TECH AGENCY (JP) | 2020-05-06 | — | — | EP | disclosed |
| US-10588896-B2 | Agents for the treatment of retroviral infectious diseases | IMMUNOLOGIK GMBH (DE) | 2020-03-17 | — | — | US | disclosed |
| US-20200071354-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | EMORY UNIVERSITY (US) | 2020-03-05 | — | — | US | disclosed |
| US-20190105341-A1 | Compositions and Methods for Treating Alzheimer's Disease and Other Tauopathies | THE BOARD OF TRUSTEE OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2019-04-11 | — | — | US | disclosed |
| US-20190105341-A1 | Compositions and Methods for Treating Alzheimer's Disease and Other Tauopathies | THE BOARD OF TRUSTEE OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2019-04-11 | — | — | US | disclosed |
| US-20180360819-A1 | ANTI-INFLUENZA VIRUS AGENT AND SCREENING METHOD FOR ANTI-INFLUENZA VIRUS AGENT | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2018-12-20 | — | — | US | disclosed |
| US-10149860-B2 | Compositions and methods for treating alzheimer's disease and other tauopathies | Board of Trustees of the Leland Stanford Junior University, Stanford University Office of Technology Licensing (US) | 2018-12-11 | — | — | US | disclosed |
| EP-3370715-A1 | PROTEOLYSIS TARGETING CHIMERA COMPOUNDS AND METHODS OF PREPARING AND USING SAME | Yale University (US) | 2018-09-12 | — | — | EP | disclosed |
| US-20180186785-A1 | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | UNIV YALE (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180186785-A1 | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | UNIV YALE (US) | 2018-07-05 | — | — | US | disclosed |
| EP-2619184-B1 | DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME | UNIV MICHIGAN REGENTS (US) | 2018-05-23 | — | — | EP | disclosed |
| US-9938264-B2 | Proteolysis targeting chimera compounds and methods of preparing and using same | YALE UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938264-B2 | Proteolysis targeting chimera compounds and methods of preparing and using same | YALE UNIVERSITY (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170290821-A1 | ANTI-INFLUENZA VIRUS AGENT AND SCREENING METHOD FOR ANTI-INFLUENZA VIRUS AGENT | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2017-10-12 | — | — | US | disclosed |
| EP-3199181-A1 | ANTI-INFLUENZA VIRUS AGENT, AND SCREENING METHOD FOR ANTI-INFLUENZA VIRUS AGENT | Japan Science and Technology Agency (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-20170202814-A1 | AGENTS FOR THE TREATMENT OF RETROVIRAL INFECTIOUS DISEASES | IMMUNOLOGIK GMBH (DE) | 2017-07-20 | — | — | US | disclosed |
| WO-2017079267-A1 | PROTEOLYSIS TARGETING CHIMERA COMPOUNDS AND METHODS OF PREPARING AND USING SAME | YALE UNIVERSITY (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20170121321-A1 | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | YALE UNIVERSITY | 2017-05-04 | — | — | US | disclosed |
| US-20170121321-A1 | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | YALE UNIVERSITY | 2017-05-04 | — | — | US | disclosed |
| US-20170095457-A1 | COMPOSITIONS AND METHODS OF DELIVERY OF DEUBIQUITINASE INHIBITORS | PHARMAKEA, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20170095457-A1 | COMPOSITIONS AND METHODS OF DELIVERY OF DEUBIQUITINASE INHIBITORS | PHARMAKEA, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20170095457-A1 | COMPOSITIONS AND METHODS OF DELIVERY OF DEUBIQUITINASE INHIBITORS | PHARMAKEA, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20160151407-A1 | Compositions and Methods for Treating Alzheimer's Disease and Other Tauopathies | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-06-02 | — | — | US | disclosed |
| US-20160151407-A1 | Compositions and Methods for Treating Alzheimer's Disease and Other Tauopathies | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-06-02 | — | — | US | disclosed |
| US-20160151407-A1 | Compositions and Methods for Treating Alzheimer's Disease and Other Tauopathies | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-06-02 | — | — | US | disclosed |
| US-9289448-B2 | Compositions and methods for treating alzheimer's disease and other tauopathies | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289448-B2 | Compositions and methods for treating alzheimer's disease and other tauopathies | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-03-22 | — | — | US | disclosed |
| US-9289448-B2 | Compositions and methods for treating alzheimer's disease and other tauopathies | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-03-22 | — | — | US | disclosed |
| WO-2016004915-A1 | SUBSTANCES FOR THE TREATMENT OF RETROVIRAL INFECTIOUS DISEASES | IMMUNOLOGIK GMBH (DE) | 2016-01-14 | — | — | WO | disclosed |
| WO-2015183987-A1 | COMPOSITIONS AND METHODS OF DELIVERY OF DEUBIQUITINASE INHIBITORS | PHARMAKEA, INC. (US) | 2015-12-03 | — | — | WO | disclosed |
| US-9096499-B2 | Compounds for treatment of cell proliferative diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096499-B2 | Compounds for treatment of cell proliferative diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150174150-A1 | Compositions and Methods for Treating Alzheimer's Disease and Other Tauopathies | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150174150-A1 | Compositions and Methods for Treating Alzheimer's Disease and Other Tauopathies | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150174150-A1 | Compositions and Methods for Treating Alzheimer's Disease and Other Tauopathies | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-06-25 | — | — | US | disclosed |
| US-20140357673-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UNIV MICHIGAN (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140357673-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UNIV MICHIGAN (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140329901-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329901-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-06 | — | — | US | disclosed |
| US-8809377-B2 | Deubiquitinase inhibitors and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809377-B2 | Deubiquitinase inhibitors and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-08-19 | — | — | US | disclosed |
| US-8648102-B2 | Compounds for treatment of cell proliferative diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-11 | — | — | US | disclosed |
| US-8648102-B2 | Compounds for treatment of cell proliferative diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130244986-A1 | METHODS OF TREATING SKIN DISORDERS WITH CAFFEIC ACID ANALOGS | MOLECULIN LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130244986-A1 | METHODS OF TREATING SKIN DISORDERS WITH CAFFEIC ACID ANALOGS | MOLECULIN LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-8450337-B2 | Methods of treating skin disorders with caffeic acid analogs | MOLECULIN, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450337-B2 | Methods of treating skin disorders with caffeic acid analogs | MOLECULIN, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-20130129675-A1 | INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129675-A1 | INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129675-A1 | INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120214850-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | PRIEBE WALDEMAR (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214850-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | PRIEBE WALDEMAR (US) | 2012-08-23 | — | — | US | disclosed |
| EP-2487156-A1 | Compounds for treatment of cell proliferative diseases | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-1701941-B1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | UNIV TEXAS (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20120077806-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2012040527-A2 | DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20120077806-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-03-29 | — | — | US | disclosed |
| US-8119827-B2 | Compounds for treatment of cell proliferative diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119827-B2 | Compounds for treatment of cell proliferative diseases | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110275577-A1 | METHODS OF TREATING DERMATOLOGIC, GYNECOLOGIC, AND GENITAL DISORDERS WITH CAFFEIC ACID ANALOGS | MOLECULIN, LLC (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275577-A1 | METHODS OF TREATING DERMATOLOGIC, GYNECOLOGIC, AND GENITAL DISORDERS WITH CAFFEIC ACID ANALOGS | MOLECULIN, LLC (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275577-A1 | METHODS OF TREATING DERMATOLOGIC, GYNECOLOGIC, AND GENITAL DISORDERS WITH CAFFEIC ACID ANALOGS | MOLECULIN, LLC (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2011069141-A2 | INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20110021805-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021805-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-01-27 | — | — | US | disclosed |
| US-20100292229-A1 | TRYPHOSTIN-ANALOGS FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292229-A1 | TRYPHOSTIN-ANALOGS FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-11-18 | — | — | US | disclosed |
| US-7745468-B2 | tyrphostin-like compounds that display a significant potency as kinase inhibitors, cause the downregulation of c-myc proto-oncogene and inhibit the growth and survival of cancerous cell lines; antiproliferative agents | Board of Regents, University of Texas Systems The (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745468-B2 | tyrphostin-like compounds that display a significant potency as kinase inhibitors, cause the downregulation of c-myc proto-oncogene and inhibit the growth and survival of cancerous cell lines; antiproliferative agents | Board of Regents, University of Texas Systems The (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100152143-A1 | Methods of Treating Skin Disorders with Caffeic Acid Analogs | MOLECULIN, LLC (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152143-A1 | Methods of Treating Skin Disorders with Caffeic Acid Analogs | MOLECULIN, LLC (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2008005954-A2 | TRYPHOSTIN-ANALOGS FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2005058829-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058829-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11883401-B2 | Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same | DDIT3, MCL1, MYD88 | USP9X 2668/4885UCHL1 1320/4885USP5 2054/4885 |
| US-20100292229-A1 | TRYPHOSTIN-ANALOGS FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES | MYC, STAT3, MYCBP | USP9X 4451/4885UCHL1 4077/4885USP5 3468/4885 |
| US-20250295659-A1 | METHODS FOR TREATING TRAUMATIC BRAIN INJURY | CTTN, SRC, FYN | USP9X 2210/4885UCHL1 238/4885USP5 1329/4885 |
| US-10149860-B2 | Compositions and methods for treating alzheimer's disease and other tauopathies | USP9X, PSEN1, PSEN2 | USP9X 1/4885UCHL1 24/4885USP5 25/4885 |
| US-20230092294-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE RESPONSE | MYD88, NFATC1, ICOS | USP9X 1522/4885UCHL1 4026/4885USP5 2306/4885 |
| US-20260109694-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CCR10, SLC11A2, MSR1 | USP9X 4466/4885UCHL1 4491/4885USP5 4866/4885 |
| US-20100152143-A1 | Methods of Treating Skin Disorders with Caffeic Acid Analogs | CUTA, TYR, PPARA | USP9X 4553/4885UCHL1 3330/4885USP5 3332/4885 |
| US-11021513-B2 | Peptidomimetics for the treatment of norovirus infection | VIP, HAVCR2, NGLY1 | USP9X 1168/4885UCHL1 1223/4885USP5 902/4885 |
| US-11691945-B2 | USP9X inhibitors | USP9X, USP19, USP39 | USP9X 1/4885UCHL1 54/4885USP5 7/4885 |
| US-11925654-B2 | Esters of 2-deoxy-monosaccharides with anti proliferative activity | SLC2A2, SLC2A1, SLC2A4 | USP9X 4139/4885UCHL1 3059/4885USP5 3988/4885 |
| US-20110275577-A1 | METHODS OF TREATING DERMATOLOGIC, GYNECOLOGIC, AND GENITAL DISORDERS WITH CAFFEIC ACID ANALOGS | VHL, PRKDC, POLR1C | USP9X 3737/4885UCHL1 3312/4885USP5 3130/4885 |
| US-20200325130-A1 | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | NEDD4, MDM2, CBL | USP9X 203/4885UCHL1 9/4885USP5 31/4885 |
| US-20250145635-A1 | COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE | BCL9, USP9X, BCL9L | USP9X 2/4885UCHL1 420/4885USP5 170/4885 |
| US-20260125760-A1 | METHODS OF TREATMENT AND DIAGNOSIS | MCL1, BCL2L1, BCL2L11 | USP9X 909/4885UCHL1 37/4885USP5 652/4885 |
| US-20250288572-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY VASCULAR DISEASE | GLUL, GGT1, GLS | USP9X 1946/4885UCHL1 638/4885USP5 1115/4885 |
| US-20110021805-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | MYC, MKI67, MYCBP | USP9X 3371/4885UCHL1 3672/4885USP5 3228/4885 |
| US-20170121321-A1 | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | NEDD4, MDM2, CBL | USP9X 203/4885UCHL1 9/4885USP5 31/4885 |
| US-20210283139-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | UCHL5, UCHL3, UCHL1 | USP9X 99/4885UCHL1 3/4885USP5 4/4885 |
| US-11993775-B2 | Ubiquitin-specific peptidase 24 inhibitor, medicinal composition and method of delaying or reversing multidrug resistance in cancers using the same | USP24, USP36, USP47 | USP9X 56/4885UCHL1 154/4885USP5 52/4885 |
| US-20160151407-A1 | Compositions and Methods for Treating Alzheimer's Disease and Other Tauopathies | USP9X, PSEN1, PSEN2 | USP9X 1/4885UCHL1 24/4885USP5 25/4885 |
| US-11859014-B2 | Peptidomimetics for the treatment of Norovirus infection | VIP, HAVCR2, NGLY1 | USP9X 1168/4885UCHL1 1223/4885USP5 902/4885 |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | PTPRCAP, PTPN2, PTPRC | USP9X 2195/4885UCHL1 2577/4885USP5 2560/4885 |
| US-20240294467-A1 | USP9X Inhibitors | USP9X, USP19, USP39 | USP9X 1/4885UCHL1 54/4885USP5 7/4885 |
| US-20240390370-A1 | Compositions for the Treatment of Pathogenic- And/Or Chemical-Induced Lung Injury and for the Treatment of Cancer and Methods of Using Same | DDIT3, MCL1, MYD88 | USP9X 2668/4885UCHL1 1320/4885USP5 2054/4885 |
| US-20230364061-A1 | THIAZOLIDINE DERIVATIVES FOR INHIBITING CAV3.2-USP5 INTERACTIONS | USP3, USP5, CACNA1I | USP9X 158/4885UCHL1 178/4885USP5 2/4885 |
| US-11446306-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | USP9X 2268/4885UCHL1 4043/4885USP5 2272/4885 |
| US-11446315-B2 | Enhancement of CD47 blockade therapy by proteasome inhibitors | CD47, PSMC1, PSMA5 | USP9X 2246/4885UCHL1 3658/4885USP5 663/4885 |
| US-20230087443-A1 | ENHANCEMENT OF CD47 BLOCKADE THERAPY BY PROTEASOME INHIBITORS | CD47, PSMC1, PSMA5 | USP9X 2261/4885UCHL1 3656/4885USP5 633/4885 |
| US-20180186785-A1 | Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same | NEDD4, MDM2, CBL | USP9X 203/4885UCHL1 9/4885USP5 31/4885 |
| US-12599592-B2 | Therapeutic small molecules for treatment of pulmonary hypertension | GSTP1, GSTK1, GSTM1 | USP9X 2208/4885UCHL1 924/4885USP5 1959/4885 |
| US-20230044323-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | NFATC1, MYD88, ICOS | USP9X 1725/4885UCHL1 3700/4885USP5 2634/4885 |
| US-20230364243-A1 | CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS | ADRM1, MYC, SKP2 | USP9X 167/4885UCHL1 535/4885USP5 547/4885 |
| US-20130244986-A1 | METHODS OF TREATING SKIN DISORDERS WITH CAFFEIC ACID ANALOGS | CUTA, TYR, PPARA | USP9X 4553/4885UCHL1 3330/4885USP5 3332/4885 |
| US-12503464-B2 | 1,2,5-thiadiazolidin-3-one 1,1-dioxide containing compounds and uses thereof | BRCA1, STING1, IFNG | USP9X 2788/4885UCHL1 4487/4885USP5 2148/4885 |
| US-20190105341-A1 | Compositions and Methods for Treating Alzheimer's Disease and Other Tauopathies | USP9X, PSEN1, PSEN2 | USP9X 1/4885UCHL1 24/4885USP5 25/4885 |
| US-20220288207-A1 | PHOTO INDUCED CONTROL OF PROTEIN DESTRUCTION | UBE3C, PSMC1, UBE3A | USP9X 173/4885UCHL1 141/4885USP5 127/4885 |
| US-11291669-B2 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent | MCL1, MYC, XIAP | USP9X 2427/4885UCHL1 3419/4885USP5 2941/4885 |
| US-20140357673-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UCHL1, USP2, USP1 | USP9X 33/4885UCHL1 1/4885USP5 19/4885 |
| US-20240398828-A1 | HETERO-ATOM CONTAINING COMPOUNDS AND USES THEREOF | CD74, HLA-DRB1, CD47 | USP9X 2444/4885UCHL1 2612/4885USP5 3358/4885 |
| US-20120214850-A1 | COMPOUNDS FOR TREATMENT OF CELL PROLIFERATIVE DISEASES | MYC, MKI67, MYCBP | USP9X 3371/4885UCHL1 3672/4885USP5 3228/4885 |
| US-20230150925-A1 | USP9X INHIBITORS | USP9X, USP19, USP39 | USP9X 1/4885UCHL1 54/4885USP5 7/4885 |
| US-20230414590-A1 | THERAPEUTIC SMALL MOLECULES FOR TREATMENT OF PULMONARY HYPERTENSION | GSTP1, GSTK1, GSTM1 | USP9X 1336/4885UCHL1 536/4885USP5 1909/4885 |
| US-20260128175-A1 | Methods and Systems for Analysis of Gene Expression Data | IRAK4, TLR4, TLR2 | USP9X 1716/4885UCHL1 2572/4885USP5 1923/4885 |
| US-20120077806-A1 | Deubiquitinase Inhibitors and Methods for Use of the Same | UCHL1, USP2, USP1 | USP9X 33/4885UCHL1 1/4885USP5 19/4885 |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SET, SSB, CNKSR1 | USP9X 731/4885UCHL1 1561/4885USP5 1058/4885 |
| US-11827611-B2 | Ubiquitin-specific peptidase 24 inhibitor, medicinal composition including the same and method of delaying or reversing multidrug resistance in cancers using the same | USP24, USP47, USP39 | USP9X 62/4885UCHL1 118/4885USP5 51/4885 |
| US-20200071354-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | VIP, HAVCR2, NGLY1 | USP9X 1168/4885UCHL1 1223/4885USP5 902/4885 |
| US-20260097224-A1 | METHODS FOR MODULATING NEUROPLASTICITY | GABRE, BDNF, GRIN2A | USP9X 4260/4885UCHL1 2347/4885USP5 4159/4885 |
| US-20130129675-A1 | INTERFERON THERAPIES IN COMBINATION WITH BLOCKADE OF STAT3 ACTIVATION | STAT3, STAT1, STAT5B | USP9X 3930/4885UCHL1 4553/4885USP5 4112/4885 |
| US-20210395300-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | VIP, HAVCR2, NGLY1 | USP9X 1168/4885UCHL1 1223/4885USP5 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.